RBC Capital Upgrades Neumora Therapeutics to Outperform, Raises Price Target to $7
Benzinga Newsdesk 11 months ago
NewsUpgradesPrice TargetAnalyst Ratings
RBC Capital analyst Brian Abrahams upgrades Neumora Therapeutics (NASDAQ:NMRA) from Sector Perform to Outperform and raises the price target from $4 to $7.
RBC Capital analyst Brian Abrahams upgrades Neumora Therapeutics (NASDAQ:NMRA) from Sector Perform to Outperform and raises the price target from $4 to $7.